Cipla Limited is an Indian pharmaceutical company, Founded by nationalist Indian scientist Khwaja
Hamied as The
Laboratories .Cipla laid foundations for the Indian pharmaceutical industry way back in 1935 with the vision to make India self-reliant and self-sufficient in healthcare. Legacy of innovation and an entrepreneurial spirit ingrained by the founder, Dr. K.A Hamied and propounded by the present Chairman and Managing Director, Dr. Yusuf Khwaja Hamied .Over the past 77 years, Cipla has emerged as one of the most respected pharmaceutical names not just in India but worldwide. The company‟s headquarter is in Mumbai, India. Cipla produces one of the widest range of products and dosage forms in the world today, everything from metered-dose inhalers, pre-filled syringes, trans-dermal spray patches, lyophilized injections, nasal sprays, medical devices, and thermo labile foams. The company Revenue is around 6977million and turnover is around 1 billion. Cipla‟s Business model is based on international strategic alliances and focus on pursuing organic growth while reducing capital commitment and regulatory/litigation risks. Cipla makes drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions, and its products are distributed in virtually every country of the world. And probably best-known outside its home country for pioneering the manufacture of low-cost anti-AIDS drugs for HIV-positive patients in developing countries. It has played a similarly prominent role in expanding access to drugs to fight influenza, respiratory disease and cancer.
Cipla has over 34 state-of-the-art manufacturing units which have been approved by various Ministries of Health and Regulatory Authorities like US FDA, WHO, MCC -South Africa, MHRAUK, TGA-Australia among others. In addition, Cipla‟s manufacturing facilities are GCMP compliant in conformity with national and international standards. With over 2000 products in 65 therapeutic areas, Cipla‟s product portfolio comprises of Active Pharmaceutical Ingredients(APIs), Formulations for Human and Animal Healthcare and OTC products. Cipla has the technological powers of manufacturing products in most dosage forms across therapeutic categories, which offers the company a unique competitive advantage. Cipla has earned a name for maintaining world-class quality across all its products and services. With the dedication of its 20,000 employees, Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices and is focused towards its commitment.Cipla won Chemexcil Award excellence for exports in 1980, wins National award for successful commercialization of publicity funded R&D in 1988.Cipla received the Thomson Reuters India Innovation Award in 2012.
Cipla started with a vision to build a healthy India
MISSSION OF THE COMPANY:
To make the life of the patients better.
CIPLA RESEARCH & DEVELOPMENT
CIPLA‟S research capabilities are extensive, from Chemical Synthesis, Delivery Systems and Medical Devices to Process Engineering, Animal Health Products, Neutraceuticals and Biotechnology. Today, across 170 countries, there are millions of patients who get to use a Cipla product to prevent, to cure, or for relief from suffering. In their cure and relief lies th e ultimate purpose of what they do. At Cipla, this has been the driving force behind continuous quest for quality. The company
strive not just to meet international
specifications, but to exceed, to excel, to meet what they call the Cipla benchmark. In fact, they have set standards for the world to follow and have contributed to more than 125 monographs in the last 15 years - to British, European, US and international pharmacopoeia. Today companies from around the world seek strategic alliances with Cipla for product development, technical support and...
Please join StudyMode to read the full document